Feb 11, 2020 · (RTTNews) - Atara Biotherapeutics Inc. (ATRA) has some key milestones lined up for this year, making it a stock worth watching. Atara is focused on developing off-the-shelf, allogeneic T-cell Atara Biotherapeutics, Inc. Common Stock (ATRA) Real-Time ... ATRA Real Time Stock Quote - Get Atara Biotherapeutics, Inc. Common Stock (ATRA) last sale data in real-time at NASDAQ.com. Atara Biotherapeutics, Inc. - ATRA - Stock Price Today - Zacks View Atara Biotherapeutics, Inc. ATRA investment & stock information. Get the latest Atara Biotherapeutics, Inc. ATRA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ATRA Interactive Stock Chart | Atara Biotherapeutics, Inc ...
Stock screener for investors and traders, financial visualizations.
Atara Biotherapeutics, Inc. Common Stock (ATRA) Stock ... Atara Biotherapeutics, Inc. Common Stock (ATRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Atara Biotherapeutics, Inc. (ATRA) Stock Price, Quote ... Find the latest Atara Biotherapeutics, Inc. (ATRA) stock quote, history, news and other vital information to help you with your stock trading and investing.
(RTTNews) - Atara Biotherapeutics Inc. (ATRA) has some key milestones lined up for this year, making it a stock worth watching. Atara is focused on developing off-the-shelf, allogeneic T-cell
ATRA | Atara Biotherapeutics Inc. Stock Price & News - WSJ View the latest Atara Biotherapeutics Inc. (ATRA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Atara Biotherapeutics Inc. Stock Price (ATRA) | Barron's View today's stock price, news and analysis for Atara Biotherapeutics Inc. (ATRA). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation Atara Biotherapeutics, Inc. (ATRA) Press Releases - NASDAQ.com Mar 27, 2020 · Atara Biotherapeutics, Inc. (ATRA) Company Press Releases – Get the latest press release for Atara Biotherapeutics, Inc. and all the companies you research at NASDAQ.com
View a financial market summary for ATRA including stock price quote, trading volume, volatility, options volume, statistics, and other important company data related to ATRA (Atara Biotherapeutics Inc.) stock.
Mar 22, 2020 Real-time trade and investing ideas on Atara Biotherapeutics ATRA from the largest community of traders and investors. Get breaking news and analysis on Atara Biotherapeutics, Inc. (ATRA) stock, price quote and chart, trading and investing tools. Sep 27, 2019 Goldman Sachs has lost confidence in Atara Biotherapeutics, downgrading the stock to Sell from Neutral on Friday. Shares of the clinical-stage The 8 analysts offering 12-month price forecasts for Atara Biotherapeutics Inc among 10 polled investment analysts is to Buy stock in Atara Biotherapeutics Inc. Researching Atara Biotherapeutics (NASDAQ:ATRA) stock? View ATRA's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC Feb 21, 2020 Yarema a stock option to purchase 110,000 shares of Atara's common stock effective as of February 18, 2020, and restricted stock units to acquire Information on stock, financials, earnings, subsidiaries, investors, and executives for Atara Biotherapeutics. Use the PitchBook Platform to explore the full profile.
ATRA: Atara Biotherapeutics Inc - Stock Price, Quote and ...
ATRA: Get the latest Atara Biotherapeutics stock price and detailed information including ATRA news, historical charts and realtime prices. Atara Biotherapeutics’ Cancer Drug Might—Might!—Have ... Atara was founded in 2012 and named after Atara Ciechanover, who has since died from cancer. The company’s technology came out of work at Memorial Sloan Kettering and Australia’s QIMR Berghofer Medical Research Institute. It is working on off-the-shelf, allogeneic T-cells bioengineered from donors who have healthy immune function.
Analysts Are Bullish on These Healthcare Stocks: Bioxcel ... Currently, the analyst consensus on Atara Biotherapeutics is a Strong Buy with an average price target of $56.50, which is a 280.5% upside from current levels. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $43.00 price target. Globus Medical (GMED)